Jane Chung's Insider Trades & SAST Disclosures
Jane Chung's most recent trade in Sutro Biopharma Inc was a trade of 7,875 Common Stock done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jane Chung.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 7,875 | 100,642 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 7,875 | 7,875 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.42 per share. | 04 Mar 2025 | 2,334 | 98,308 (0%) | 0% | 1.4 | 3,314 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 25,000 | 75,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 25,000 | 102,217 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.59 per share. | 01 Mar 2025 | 9,450 | 92,767 (0%) | 0% | 1.6 | 15,026 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 6,875 | 13,750 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 6,875 | 77,217 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Chung Jane | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 25,000 | 79,262 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 25,000 | 75,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 01 Dec 2024 | 8,920 | 70,342 (0%) | 0% | 2.7 | 23,995 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 18,750 | 60,951 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2024 | 18,750 | 18,750 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 09 Aug 2024 | 6,689 | 54,262 (0%) | 0% | 3.1 | 20,870 | Common Stock |
| Viracta Therapeutics Inc | Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 100,000 | 100,000 | - | - | Restricted Stock Units (RSUs) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 7,875 | 15,750 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 7,875 | 44,410 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.79 per share. | 04 Mar 2024 | 2,209 | 42,201 (0%) | 0% | 4.8 | 10,581 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 6,875 | 38,573 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 6,875 | 20,625 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | PRESIDENT AND COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.95 per share. | 01 Mar 2024 | 2,038 | 36,535 (0%) | 0% | 4.9 | 10,088 | Common Stock |
| Sutro Biopharma Inc | Chung Jane | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 100,000 | 100,000 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 18,750 | 37,500 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2023 | 18,750 | 38,181 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.22 per share. | 09 Aug 2023 | 6,483 | 31,698 (0%) | 0% | 4.2 | 27,358 | Common Stock |
| Viracta Therapeutics Inc | Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 27,500 | 27,500 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 7,875 | 23,625 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 7,875 | 22,642 (0%) | 0% | - | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.79 per share. | 03 Mar 2023 | 3,211 | 19,431 (0%) | 0% | 5.8 | 18,592 | Common Stock |
| Viracta Therapeutics Inc | Jane Chung | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 18,750 | 56,250 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2022 | 18,750 | 21,250 (0%) | 0% | 0 | Common Stock | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.60 per share. | 09 Aug 2022 | 6,483 | 14,767 (0%) | 0% | 6.6 | 42,788 | Common Stock |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 31,500 | 31,500 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 160,000 | 160,000 | - | - | Stock Option (right to buy) | |
| Sutro Biopharma Inc | Jane Chung | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2021 | 75,000 | 75,000 | - | - | Restricted Stock Unit (RSU) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges